In the treatment of viral infections with pyrimidine analogues, on the other hand, the haematological side-effects are incidental though none the less hazardous. However, the functional reserve of normal marrow is considerable. Haemopoietic cell-lines can be considered divided into three compartments: stem cells, maturing ('committed') cells, and functional cells (Fig. 1 ). Proliferation occurs, albeit slowly, in the stem-cell compartment, which has the dual role of self-maintenace and of providing cells for the maturation pathway: their numbers and proliferation rates are under homeostatic control. Proliferation is also occurring amongst the earlier members of the maturing cell compartment. In the normal marrow, events in this compartment dominate the proliferative characteristics of the tissue (Lamerton & Steel, 1968; Lamerton, 1972) . It has been demonstrated in experimental animals that stem cells account for only about 1%. or less, of the proliferating cells present in the marrow; the remainder are in the maturing compartment, which are also dividing much more rapidly (Lahiri & van Putten, 1969) . The rate of production of mature erythrocytes, granulocytes and platelets depends on the intermitotic time of the dividing cells; in the maturing compartment this is probably a matter of hours, whereas in the stem-cell compartment, divisions occur much less frequently. Thus, in the marrow, there is a small, normally slowly dividing stem-cell compartment and a much larger and rapidly-dividing population of later committed precursors. The capacity of the marrow to withstand damage by cytotoxic drugs depends on two critical factors: (1) the speed with which the stem-cell population can regenerate following death of more mature cells and (2) the number of stem cells required.
Pyrimidine analogues are 'phase-specific' drugs, that is, they act only on replicating cells during the S-phase of the cycle. They appear to have no effect on stem cells, or on 'resting cells' (in Go). Since the dividing cells are not in synchrony, but are entering S-phase at different times, it has been held that the cytotoxic action of these drugs is enhanced if given as a slow continuous infusion: there is some support from haematological practice that this is so (Ellison et al., 1968) .
In rats, it has been shown that, following obliteration of all recognizable granulocyte and erythroblast precursor cells with methotrexate, the stem-cell population re-establishes haemopoietic function so rapidly that red cell and granulocyte production are back to 50/4 of their normal values 31 and 6 days, respectively, after the production of aplasia (Blackett, 1968) . In man, regeneration is slower, but it is important to realize that in aplasia produced by pyrimidine analogues, recovery can be expected if the patient has normal marrow reserve and can be protected during the aplastic phase. The situation is thus different from that in idiopathic aplasia, or that due to some drugs, in which concomitant damage to the microvasculature of the marrow, possibly mediated by an immunological mechanism, delays or prevents recovery. On the other hand, patients with reduced marrow function may suffer prolonged hypoplasia. These include the elderly, those with malignant haematological disorders, hepatic or renal disease, overwhelming toxaemia or previous malnutrition.
Therapy with IDU and Ara-C There are now a number of reports of treatment of viral infections with systemic pyrimidine analogues. Haematological side-effects have been variable and apparently unpredictable: thus Nolan and his colleagues reported troublesome leucopenia and thrombocytopenia after the use of IDU (Nolan, Carruthers & Lever, 1970) . On the other hand, JuelJensen (1971) treated five cases of disseminated herpetic infection with Ara-C at a dosage of 2 mg/kg body weight without any signs of marrow depression, and Longson reported no haematological side-effects in patients treated with IDU at a dosage of 100 mg/kg body weight. Figures 2 and 3 represent the haematological progress of two haematologically normal patients treated, respectively, with Ara-C and IDU. The onset of marrow depression is not usually noted until about the seventh day; it is usual to give pyrimidine analogues in 'pulses' over 3-5 days, and the pancytopenia may not appear until after the drug has been withdrawn. Thrombocytopenia is often the first sign of marrow damage, though examination of the marrow will show toxic changes much earlier; for example striking megaloblastosis is a feature of treatment with Ara-C, and develops within hours. Marrow aspiration later will show hypoplasia or aplasia; thus in the patient illustrated in Fig. 1 (Fig. 2) .
The hypoplastic phase Once severe marrow hypoplasia is established, therapy with the analogue must be stopped. Withdrawal of the drug may be sufficient, but a prolonged aplastic episode is a serious complication, even though eventual marrow recovery can be expected. (Sanchez-Medal et al., 1969 ). It appears to be more effective in stimulating erythropoiesis than leucopoiesis or thrombopoiesis, but the clinical manifestations of bleeding usually disappear in those patients responding to the drug.
